The proposed Phase 2, single-center, fixed dose, open-label study will explore the efficacy, safety, and tolerability of 25 mg dose of oral psilocybin in conjunction with therapy in cisgender women participants diagnosed with PTSD secondary to an index trauma of sexual assault.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault
Timeframe: Between ICF until End of Study (approx. 8 weeks from baseline)
To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault
Timeframe: Between Baseline to End of Study (approx. 8 weeks from baseline)
Clinical Evaluation Team